- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program | 1 | GlobeNewswire (USA) | ||
| SHUTTLE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 19.12. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12. | Shuttle Pharmaceuticals stock hits 52-week low at $0.67 | 2 | Investing.com | ||
| 16.12. | Aktie von Shuttle Pharmaceuticals erreicht 52-Wochen-Tief bei 0,67 US-Dollar | 1 | Investing.com Deutsch | ||
| 06.12. | SHPH stock touches 52-week low at $0.75 amid market challenges | 1 | Investing.com | ||
| 06.12. | SHPH-Aktie erreicht 52-Wochen-Tief bei 0,75 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.11. | Aktie von Shuttle Pharmaceuticals erreicht 52-Wochen-Tief bei 0,83 US-Dollar | - | Investing.com Deutsch | ||
| 26.11. | Shuttle Pharmaceuticals stock hits 52-week low at $0.83 | 1 | Investing.com | ||
| 26.11. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient | 86 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused... ► Artikel lesen | |
| 26.11. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | SHPH-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.11. | SHPH stock touches 52-week low at $1.02 amid market challenges | 1 | Investing.com | ||
| 13.11. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Third Quarter 2024 Corporate Update | 90 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical... ► Artikel lesen | |
| 13.11. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Shuttle Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10. | Shuttle Pharmaceuticals dips 6%, prices $3.5M share offering | 3 | Seeking Alpha | ||
| 30.10. | Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 3 | GlobeNewswire (USA) | ||
| 29.10. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma | 109 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused... ► Artikel lesen | |
| 29.10. | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 459 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| 29.10. | Shuttle Pharma Updates On Clinical Trial Site; Stock Surges | 6 | RTTNews |
Seite:
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,000 | -1,64 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| ROCKET LAB USA | 24,700 | +0,41 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
| BOIRON | 26,300 | +3,75 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 33,450 | 0,00 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| ESSA PHARMA | 1,620 | 0,00 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| MEDICINOVA | 2,020 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,515 | 0,00 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
| LYRA THERAPEUTICS | 0,169 | 0,00 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 2,520 | 0,00 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,795 | 0,00 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 7,890 | 0,00 % | Reneo Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 7,91 US-Dollar | ||
| OMNIAB | 3,520 | 0,00 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen |
Das Unternehmen SHUTTLE PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,845 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHUTTLE PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
